NewTimeSpace News: UNITED LAB (03933.HK) announced that its subsidiary United Biotech received US$13.5 million milestone payment (after Danish withholding tax) from Novo Nordisk for completing global Phase II clinical trial of UBT251 injection for overweight and obesity indication. Under the previously executed exclusive licence agreement, United Biotech is eligible for potential milestone payments of up to US$1.8 billion plus tiered royalties on sales.
NewTimeSpace (newtimespace.com) reported that on July 16, 2026, the humanoid robot theme fluctuated, with UBTECH (09880.HK) strengthening in choppy trading. As of 13:10, the stock was quoted at HKD 88.450, up 3.15%.
NewTimeSpace News: SSY GROUP (02005.HK) announced that the Group has obtained the drug production registration approval issued by NMPA for Choline Fenofibrate Sustained-release Capsule (135mg). Classified as Category 4 chemical drug, it is deemed to have passed consistency evaluation. The product is mainly applied to reduce triglyceride levels in patients with severe hypertriglyceridemia and treat primary hypercholesterolemia.
NewTimeSpace News: JENSCARE-B (09877.HK) announced that LuX-Valve Plus, its self-developed transcatheter tricuspid valve replacement system, has recently completed the first subject implantations in the FDA-approved US pivotal registration trial, marking a breakthrough progress in its US clinical programme. The trial will conduct head-to-head randomised control against Edwards Lifesciences’ EVOQUE system.
Dobot announced on July 15 that its ChiNext IPO will be reviewed by the listing committee on July 22, taking only 86 days from acceptance to hearing, sponsored by Guotai Haitong Securities with planned proceeds of approximately RMB1.2 billion. The Company ranked first globally in collaborative robot shipments in 2025 with cumulative installations exceeding 100,000 units, and H1 2026 embodied intelligence shipment value exceeded RMB40 million with 231 accumulated customers. Revenue grew from RMB287 million in 2023 to RMB493 million in 2025, with net losses narrowing year by year. Proceeds allocation: RMB550 million for multi-legged robots and RMB250 million for humanoid robots. Listed on the Hong Kong Stock Exchange in December 2024, this A-share listing if successful would become the first "H-to-A" case in the Greater Bay Area following the Shenzhen comprehensive reform pilot program.
IngDan announced on July 16 that the Group has completed its strategic upgrade from an AI hardware distributor to a vertical AI Token factory operator, having cumulatively signed intent service orders exceeding US$1 billion with customers including global tier-one cloud service providers, embodied intelligence companies and AI model companies. The Group has established a vertical industry Token computing power scheduling platform with a revenue sharing model and dual-track infrastructure deployment. The Board believes the Group has established a first-mover advantage in the vertical AI computing power track and will develop Token operation services as its second growth curve. The intent orders are not yet signed contracts, and actual revenue recognition will depend on service agreement execution and business conditions.
NewTimeSpace News: Hengrui Pharmaceuticalsannounced on July 15 that its subsidiary Beijing Shengdi Pharmaceutical Co., Ltd. has obtained the Clinical Trial Approval Notice for Concentrated Solution for Injection HRS-8829 issued and approved by the National Medical Products Administration (NMPA).
NewTimeSpace News: On 15 July, InnoCare Pharma Limitedannounced that Soficitinib (ICP-332), a new-generation oral TYK2 inhibitor independently developed by the Company, successfully met the primary endpoint in its Phase III registrational clinical trial for the treatment of moderate-to-severe atopic dermatitis.
On July 15, Hong Kong equities closed higher, with the LLM sector staging a powerful rebound. Spurred by a sharp drop in Fed rate-hike expectations following a cooler-than-expected US June CPI, the domestic large model "duopoly" surged, with MiniMax gaining over 13% and ZHIPU AI rising more than 6%. On the infrastructure front, WAIC 2026 is set to open with record-breaking exhibition scales, where AI intelligent computing and embodied AI stand out as core focus areas with over 200 exhibitors each; meanwhile, ZHIPU AI established a wholly owned application research institute in Hangzhou. In edge AI developments, Apple is reportedly in talks with PrismML to deploy highly compressed large models natively on iPhones, aiming to deliver low-latency, offline capabilities while securing its signature privacy framework.
NewTimeSpace News: China Medical System Holdingsannounced on 15 July that capsules of CMS-D017, an innovative self-developed complement factor B inhibitor, have obtained the clinical trial approval notice issued by the National Medical Products Administration (NMPA).
NewTimeSpace News: Ascletis Pharma announced on 15 July that the Company has selected a fixed-dose combination (FDC) of ASC48, a first-in-class oral small-molecule GIPR agonist, and ASC30, an oral small-molecule GLP-1R agonist, for clinical development. An Investigational New Drug (IND) application is expected to be submitted to the FDA in the fourth quarter of 2026.
NewTimeSpace News: HBM Holdings announced on 15 July that the Investigational New Drug (IND) application for HBM7575, a long-acting bispecific antibody targeting TSLP and an undisclosed target, has been approved by the National Medical Products Administration (NMPA) for the treatment of asthma.
NewTimeSpace News: On 15 July 2026, RoboSense (02498.HK) edged higher in the afternoon. As of 15:30, the stock traded at HK$22.40, up 0.99%. Institutions maintain a bullish stance on the L4 RoboX theme for 2026.
NewTimeSpace (newtimespace.com) reported that Hong Kong semiconductor‑related themes experienced a volatile pullback, with HUA HONG GRACE (01347.HK) weakening. As of 13:27, the stock was quoted at HKD 168.100, down 1.98%.
NewTimeSpace (newtimespace.com) reported that on July 15, 2026, the robotics theme in Hong Kong stocks fluctuated lower, while Midea Group (00300.HK) rose in volatile trading. As of 13:13, the stock was quoted at HKD 92.300, up 3.07%.
NewTimeSpace (newtimespace.com) News, On July 15, 2026, Hong Kong-listed AI agent concept stocks rallied collectively, with stocks such as MINIMAX-W (0100.HK), Zhipu (2513.HK), and Mininglamp Technology (2718.HK) delivering stellar performances. As of 10:20, MINIMAX-W (0100.HK) was quoted at HK$257.000, leading the gains among a crowd of large model concept stocks with an 11.74% surge.
